Leukemia  >>  Gazyva (obinutuzumab)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

28 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Gazyva (obinutuzumab) / Roche, Biogen
NCT01010061: CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a)

Checkmark EHA 2016
May 2016 - May 2016: EHA 2016
Checkmark EHA 2016
May 2016 - May 2016: EHA 2016
Checkmark ISH 2016
More
Completed
3
787
Canada, US, Europe, RoW
obinutuzumab, RO5072759, GA101, GAZYVA®, rituximab, Rituxan®, MabThera®, chlorambucil
Hoffmann-La Roche, German CLL Study Group, Genentech, Inc.
Lymphocytic Leukemia, Chronic
07/12
08/17
NCT01998880: CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)

Completed
3
787
Canada, US, Europe, RoW
obinutuzumab, RO5072759, GA101, GAZYVA®, rituximab, Rituxan®, MabThera®, chlorambucil
Hoffmann-La Roche, German CLL Study Group, Genentech, Inc.
Lymphocytic Leukemia, Chronic
08/12
08/17
NCT02053610: CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)

Completed
3
787
Canada, US, Europe, RoW
obinutuzumab, RO5072759, GA101, GAZYVA®, Gazyvaro, rituximab, Rituxan®, MabThera®, chlorambucil
Hoffmann-La Roche, German CLL Study Group, Genentech, Inc.
Lymphocytic Leukemia, Chronic
08/13
08/17
NCT01980875 / 2013-004551-20: Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Terminated
3
57
Canada, US, Europe, RoW
Idelalisib, GS-1101, CAL-101, Zydelig®, Chlorambucil, Obinutuzumab
Gilead Sciences
Chronic Lymphocytic Leukemia
05/16
05/16
NCT01905943 / 2013-000087-29: A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia

Checkmark EHA 2016
May 2016 - May 2016: EHA 2016
Completed
3
979
Europe, Canada, RoW
Bendamustine, Chlorambucil, Cyclophosphamide, Fludarabine, Obinutuzumab, Gazyva®, RO5072759
Hoffmann-La Roche
Chronic Lymphocytic Leukemia
12/16
10/18
iLLUMINATE , NCT02264574 / 2014-002069-31: A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Checkmark From iLLUMINATE trial in combination with Gazyva for 1L CLL/SLL
Dec 2020 - Dec 2020: From iLLUMINATE trial in combination with Gazyva for 1L CLL/SLL
Checkmark iLLUMINATE trial in combination with Gazyva for 1L CLL/SLL at ASH 2018
Dec 2018 - Dec 2018: iLLUMINATE trial in combination with Gazyva for 1L CLL/SLL at ASH 2018
Checkmark iLLUMINATE trial in combination with Gazyva for 1L CLL/SLL
More
Completed
3
229
Europe, Canada, US, RoW
Ibrutinib, Obinutuzumab, Chlorambucil
Pharmacyclics LLC.
Chronic Lymphocytic Leukemia, Small-Cell Lymphoma
03/18
09/19
CLL14 study, NCT02242942 / 2014-001810-24: Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

Checkmark 4 year data from trial in combination with obinutuzumab for previously untreated CLL at ASH 2020
Dec 2020 - Dec 2020: 4 year data from trial in combination with obinutuzumab for previously untreated CLL at ASH 2020
Checkmark From CLL-14 trial in combination with Gazyva in CLL
Sep 2020 - Sep 2020: From CLL-14 trial in combination with Gazyva in CLL
Checkmark From CLL-14 trial in combination with Gazyva in CLL at ASCO 2020
More
Active, not recruiting
3
445
Europe, Canada, US, RoW
Chlorambucil, Venetoclax, ABT-0199, GDC-0199, Obinutuzumab, GA-101; Gazyva
Hoffmann-La Roche, AbbVie, German CLL Study Group
Lymphocytic Leukemia, Chronic
08/18
08/25
ELEVATE-TN, NCT02475681 / 2014-005582-73: Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

Hourglass Dec 2023 - Dec 2023 : Data from ELEVATE-TN in treatment-naive chronic lymphocytic leukemia at ASH 2023
Checkmark 5-year PFS data from ELEVATE CLL TN trial for CLL at ASCO 2022
Jun 2022 - Jun 2022: 5-year PFS data from ELEVATE CLL TN trial for CLL at ASCO 2022
Checkmark Presentation of data from ELEVATE TN trial in combination with obinutuzumab for 1L CLL at ASCO 2022
Jun 2022 - Jun 2022: Presentation of data from ELEVATE TN trial in combination with obinutuzumab for 1L CLL at ASCO 2022
More
Active, not recruiting
3
535
Europe, Canada, US, RoW
Acalabrutinib, ACP-196 (Calquence), Obinutuzumab, GAZYVA / GAZYVARO, Chlorambucil, LEUKERAN
Acerta Pharma BV
Chronic Lymphocytic Leukemia
02/19
09/25
2018-002443-28: This study is being done to test the effectiveness and safety of an investigational drug called acalabrutinib (ACP-196) when taken with already marketed drugs called Venetoclax and Obinutzumab in comparison to chemotherapy that is already in wide use for treatment of patients who have chronic lymphocytic leukemia and who have never been treated before.

Not yet recruiting
3
780
Europe, RoW
acalabrutinib, ACP-196, Capsule, hard, Concentrate for solution for infusion, Powder for solution for injection/infusion, Concentrate for solution for injection/infusion, Film-coated tablet, Powder for concentrate for solution for infusion, Gazyvaro, MABTHERA, Venclyxto
Acerta Pharma B.V., ACERTA PHARMA BV, AstraZeneca, Acerta Pharma B.V., AstraZeneca AB, ASTRAZENECA AB, Acerta BV
Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation, Previously untreated low-risk blood cancer, Diseases [C] - Cancer [C04]
 
 
2019-003327-37: A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) without DEL (17P) or TP53 mutation Estudio para comparar la eficacia y seguridad de un régimen combinado de Venetoclax y Obinutuzumab versus fludarabina, ciclofosfamida y rituximab (FCR) / bendamustina y rituximab (BR) en pacientes FIT con leucemia linfocítica crónica (CLL) sin tratamiento previo sin DEL (17P) o mutación TP53

Not yet recruiting
3
165
Europe
Venclexta®, Venclyxto® or GDC-0199, Obinutuzumab, MabThera, Bendamustine, Cyclophosphamide, Fludarabine, Venclexta®, Venclyxto® or GDC- 0199, RO5537382, RO5072759, RO0452294, Film-coated tablet, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Powder for solution for injection/infusion, Venclyxto® 10 mg film-coated tablets, Gazyvaro, MabThera 500 mg concentrate for solution for infusion, Venclyxto® 50 mg film-coated tablets, Venclyxto® 100 mg film-coated tablets
F. Hoffmann-La Roche Ltd, F. HOFFMANN - LA ROCHE LTD., F. Hoffmann-La Roche Ltd
Chronic Lymphocytic Leukemia (CLL) Leucemia Linfocítica Crónica (LLC), CLL is a type of a cancer in which the bone marrow (BM) makes too many lymphocytes (a type of white blood cell) LLC es un tipo de cáncer en el cual la médula ósea (MO) produce demasiados linfocitos (un tipo de glóbulo blanco), Diseases [C] - Cancer [C04]
 
 
GLOW, NCT03462719 / 2017-004699-77: A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Checkmark New data from the P3 GLOW study in combination with ibrutinib in 1L CLL/SLL at ASH 2022
Dec 2022 - Dec 2022: New data from the P3 GLOW study in combination with ibrutinib in 1L CLL/SLL at ASH 2022
Checkmark Data from GLOW trial in combination with Venclexta for CLL at ASH 2021
Dec 2021 - Dec 2021: Data from GLOW trial in combination with Venclexta for CLL at ASH 2021
Checkmark Presentation of data from GLOW trial in combination with Venclexta for CLL/SLL at EHA 2021
More
Active, not recruiting
3
211
Europe, Canada, US, RoW
Ibrutinib, Venetoclax, Chlorambucil, Obinutuzumab, Ibrutinib (as Subsequent Therapy)
Janssen Research & Development, LLC, Pharmacyclics LLC.
Leukemia, Lymphocytic, Chronic, B-Cell
02/21
04/27
NCT02035462 / 2009-012476-28: CLL11: A Study of RO5072759 (GA101) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Active, not recruiting
3
787
US, Canada, Europe, RoW
RO5072759, rituximab, chlorambucil
Hoffmann-La Roche, F. Hoffmann-La Roche Ltd., , F.Hoffmann-La Roche Ltd.
Lymphocytic Leukemia, Chronic
06/21
06/21
2020-004360-26: Comparison of a fixed-duration treatment of acalabrutinib, venetoclax and obinutuzumab to a treatment of venetoclax and obinutuzumab in patients with high risk chronic lymphocytic leukemia Vergleich einer befristeten Therapie mit Acalabrutinib, Venetoclax und Obinutuzumab mit der Therapie von Venetoclax und Obinutuzumab bei Patienten mit chronischer lymphytischer Leukämie mit hohem Risiko

Not yet recruiting
3
178
Europe
Acalabrutinib, Obinutuzumab, Venetoclax, RO5072759, Capsule, hard, Concentrate for solution for infusion, Film-coated tablet, Calquence, Gazyvaro®, Venclyxto
German CLL Study Group (University of Cologne), AstraZeneca
Patients with previously untreated chronic lymphocytic leukemia with treatment requiring disease and at least one out of three risk factors (17p-deletion, TP53 mutation or Complex karyotype)., Patients with chronic lymphocytic leukaemia (blood cancer) in need of firstline treatment and at least one out of three risk factors., Diseases [C] - Cancer [C04]
 
 
NCT03406156: A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

Completed
3
120
US
Obinutuzumab, Gazyva, Bendamustine, Bendeka, Venetoclax, Venclexta, ABT-199, GDC-0199
AbbVie
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
10/21
07/23
UNITY-CLL, NCT02612311 / 2015-005758-36: Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia

Checkmark Withdrawn sNDA filing in combination with ublituximab for adult patients with CLL and SLL
Apr 2022 - Apr 2022: Withdrawn sNDA filing in combination with ublituximab for adult patients with CLL and SLL
Checkmark From UNITY-CLL trial in combination with ublituximab for r/r CLL at ASH 2021
Dec 2021 - Dec 2021: From UNITY-CLL trial in combination with ublituximab for r/r CLL at ASH 2021
Checkmark From UNITY-CLL trial in combination with ublituximab for r/r CLL at iwCLL 2021
More
Terminated
3
603
Europe, US, RoW
Obinutuzumab, GAZYVA, Ublituximab, TGR-1202, Chlorambucil, Leukeran
TG Therapeutics, Inc.
Chronic Lymphocytic Leukemia
02/23
02/23
GAIA, NCT02950051 / 2015-004936-36: Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

Hourglass Jan 2021 - Dec 2021 : From CLL13 trial in combination with Venclexta for 1L CLL
Completed
3
926
Europe, RoW
Fludarabine, Fludura, Cyclophosphamide, Endoxan, Rituximab, MabThera, Rituxan, Bendamustine, Ribomustin, Levact, Venetoclax, Venclexta, Venclyxto, Obinutuzumab, Gazyva, Gazyvaro, Ibrutinib, Imbruvica
German CLL Study Group, Janssen-Cilag Ltd., Hoffmann-La Roche, AbbVie, Stichting Hemato-Oncologie voor Volwassenen Nederland, Nordic CLL Study Group (NCLLSG), Swiss Group for Clinical Cancer Research, Cancer Trials Ireland, Israeli CLL Study Group
Chronic Lymphocytic Leukemia
02/24
02/24
CRISTALLO, NCT04285567: A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation

Active, not recruiting
3
166
Europe, US, RoW
Obinutuzumab, Gazyva, RO5072759, GA101, Venetoclax, Venclexta, RO5537382, GDC-0199, Fludarabine, Cyclophosphamide, Rituximab, MabThera, Rituxan, Bendamustine, Treanda, Levact, Ribomustin
Hoffmann-La Roche
Chronic Lymphocytic Leukemia (CLL)
03/24
07/26
NCT06428019: A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Not yet recruiting
3
120
NA
Venetoclax, ABT-199, Acalabrutinib, Obinutuzumab
AbbVie
Chronic Lymphocytic Leukemia
10/26
10/26
NCT05197192 / 2020-004360-26: A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL

Recruiting
3
650
Europe
Obinutuzumab, Gazyva, Gazyvaro, Venetoclax, Venclexta, Venclyxto, Acalabrutinib, Calquence
German CLL Study Group, AstraZeneca
Chronic Lymphocytic Leukemia
05/26
02/27
NCT05211856: Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

Recruiting
3
780
Europe, Canada, US, RoW
Acalabrutinib, Calquence (acalabrutinib), Venetoclax, Venclyxto, Venclexta, Chemoimmunotherapy, Obinutuzumab, Gazyva, Gazyvaro
AstraZeneca
Chronic Lymphocytic Leukemia
01/27
01/27
ACE-CL-311, NCT03836261: Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL

Calendar Jan 2027 - Mar 2027: Last patient dosing of P3 ACE-CL-311 trial in combination with venetoclax for previously untreated CLL
Calendar Jan 2024 - Dec 2024: Acceptance of regulatory submission in combination with venclexta and obinutuzumab for 1L CLL (based on AMPLIFY trial)
Calendar Jan 2024 - Dec 2024: Data from AMPLIFY trial in combination with Calquence and obinutuzumab for previously untreated CLL
Hourglass Jul 2022 - Dec 2022 : From P3 ACE-CL-311 trial in combination with Venclexta for 1L CLL
Active, not recruiting
3
984
Europe, Canada, US, RoW
Acalabrutinib, Calquence (acalabrutinib), Venetoclax, Venclyxto, Venclexta, Chemoimmunotherapy, Obinutuzumab, Gazyva, Gazyvaro
Acerta Pharma BV, AstraZeneca
Chronic Lymphocytic Leukemia
01/27
01/27
CLL17, NCT04608318 / 2019-003854-99: Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Active, not recruiting
3
897
Europe, RoW
Ibrutinib, Imbruvica, Venetoclax, ABT-199, Venclyxto, Obinutuzumab, GA101, Gazyvaro
German CLL Study Group, Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Nordic CLL Study Group (NCLLSG), Swiss Group for Clinical Cancer Research (SAKK), Cancer Trials Ireland, Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), Grupo Español de Leucemia Linfocítica Crónica (GELLC), The Israeli CLL Study Group (ICLLSG)
Chronic Lymphoid Leukemia
03/27
03/27
MAJIC, NCT05057494 / 2021-003936-10: A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Active, not recruiting
3
607
Europe, US, RoW
Acalabrutinib, Venetoclax, Obinutuzumab
AstraZeneca
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
07/27
04/29
A041702, NCT03737981: Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

Active, not recruiting
3
454
US
Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Observation, Inspection, Visual Inspection, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
06/27
06/27
NCT03701282: Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

Active, not recruiting
3
720
US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Ibrutinib, BTK Inhibitor PCI-32765, CRA-032765, Imbruvica, PCI-32765, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Quality-of-Life Assessment, Quality of Life Assessment, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
05/28
05/28
EVOLVE CLL/SLL, NCT04269902: Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), Study

Recruiting
3
247
Canada, US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Obinutuzumab, Anti-CD20 Monoclonal Antibody R7159, GA-101, GA101, Gazyva, huMAB(CD20), R7159, RO 5072759, RO-5072759, RO5072759, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Venetoclax, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto
National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
10/28
10/28
CELESTIAL-TNCLL, NCT06073821: Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

Recruiting
3
640
Europe, Canada, US, RoW
Sonrotoclax, BGB-11417, Zanubrutinib, BGB-3111, Venetoclax, Obinutuzumab
BeiGene
CLL
02/32
12/32
2014-000880-42: A phase II/III trial to assess the use of obinutuzmab against no treatment in patients who have recently had a good response to previous treatment for Chronic Lymphocytic Leukaemia (CLL)

Ongoing
2/3
188
Europe
Obinutuzumab, GA-101, Concentrate for solution for infusion, Gazyvaro
University of Leeds, Cancer Research UK/Clinical Trials Advisory and Awards Committee (CRUK/CTAAC), Roche Products Ltd
Chronic Lymphocytic Leukaemia (CLL)., Chronic Lymphocytic Leukaemia (CLL)., Diseases [C] - Blood and lymphatic diseases [C15]
 
 

Download Options